PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arthrestherBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleArthritis Research & Therapy
 
Arthritis Res Ther. 2010; 12(3): R80.
Published online May 11, 2010. doi:  10.1186/ar3005
PMCID: PMC2911862
Natural killer cells control a T-helper 1 response in patients with Behçet's disease
Yukie Yamaguchi,1,2 Hayato Takahashi,3 Takashi Satoh,1 Yuka Okazaki,1 Nobuhisa Mizuki,4 Kazuo Takahashi,2 Zenro Ikezawa,2 and Masataka Kuwanacorresponding author1
1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
2Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
3Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
4Department of Ophthalmology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
corresponding authorCorresponding author.
Yukie Yamaguchi: yui1783/at/yahoo.co.jp; Hayato Takahashi: hayato/at/sc.itc.keio.ac.jp; Takashi Satoh: dm02019v/at/st.kitasato-u.ac.jp; Yuka Okazaki: mi081004/at/sc.itc.keio.ac.jp; Nobuhisa Mizuki: mizunobu/at/med.yokohama-cu.ac.jp; Kazuo Takahashi: kazu2667/at/med.yokohama-cu.ac.jp; Zenro Ikezawa: ik4512/at/med.yokohama-cu.ac.jp; Masataka Kuwana: kuwanam/at/sc.itc.keio.ac.jp
Received July 21, 2009; Revised December 22, 2009; Accepted May 11, 2010.
Abstract
Introduction
Behçet's disease (BD) is a multisystem inflammatory disorder, in which a T-helper 1 (Th1)-polarized immune response plays a major role in the pathogenic process. We evaluated the regulatory role of natural killer (NK) cells in Th1-biased immune responses in patients with BD.
Methods
We studied 47 patients with BD, including 10 with active disease (aBD) and 37 with inactive disease (iBD), and 29 healthy controls. The activation status and cytotoxic activity of NK cells were examined by flow cytometry. The levels of mRNAs for immune modulatory and cytotoxic molecules in NK cells were determined by quantitative PCR. The IL-12 signal strength in NK cells was determined by assessing the phosphorylation state of its downstream component, signal transducer and activator of transduction 4, by immunoblotting. Finally, NK cells' ability to modulate the Th1 response was evaluated by co-culturing NK cells and T cells without cell contact.
Results
CD69+-activated NK cells were significantly increased in aBD compared with iBD or control samples, although their cytotoxic activities were similar. The iBD NK cells showed downregulated IL-12 receptor β2 mRNA levels compared with aBD or control NK cells. The increased IL-13 expression was detected in a subset of BD patients: most of them had iBD. The IL-13 expression level in iBD patients was significantly higher than the level in controls, but was not statistically different compared with the level in aBD patients. The gene expression profile in iBD patients was consistent with the NK type 2 phenotype, and the shift to NK type 2 was associated with disease remission. NK cells from iBD patients showed impaired IL-12-induced signal transducer and activator of transduction 4 phosphorylation. Finally, iBD, but not control, NK cells suppressed IFNγ expression by aBD-derived CD4+ T cells in vitro.
Conclusions
NK cells may control disease flare/remission in BD patients via NK type 2-mediated modulation of the Th1 response.
Articles from Arthritis Research & Therapy are provided here courtesy of
BioMed Central